- A higher biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) offered improved OS in patients with stage II, node-negative (N0) NSCLC, but not node-positive (N1) disease.
Why this matters
- SBRT has demonstrated survival benefit in stage I NSCLC, but is infrequently used for stage II disease.
- 56,543 patients with stage II NSCLC from the National Cancer Database.
- 19.3-month median follow-up.
- Funding: None.
- 451 patients (0.8%) received SBRT.
- Of these, 79.8% had N0 and 20.2% had N1 disease.
- 92.7% of SBRT patients were prescribed BED10≥100 Gy; 28.4% received BED10≥114.9 Gy.
- Overall, median OS was longer for patients who received BED10≥114.9 Gy vs BED10
- No significant OS difference between patients who received BED10≥100 Gy vs those who received BED10
- 30-day mortality after SBRT was similar between groups.
- An SBRT dose of BED10≥114.9 Gy was associated with better OS (aHR, 0.72; P=.037).
- Among N0 patents, better survival was associated with increasing BED10 as a continuous variable (aHR, 0.991; P=.0009) and BED10≥114.9 Gy as a dichotomous variable (aHR, 0.63; P=.015).
- Retrospective study.